Antibody testing will help provide a greater understanding of the virus, including how long antibodies stay in the body and how much of the population has been infected.
Through the launch of the Innovation Lab, Sherlock said it can develop the INSPECTR-based test to meet the global need for increased testing capacity.
The companies said they will train, model, and expand insights continuously using machine learning and artificial intelligence, with the goal of enabling early identification of people at high risk for PTSD and other behavioral health conditions based on their biomarkers.
The primary objective of the collaboration is to broaden patient access to genomic testing inclusive of NTRK1, NTRK2, and NTRK3 gene fusions and to help improve identification of appropriate treatment options for patients with TRK fusion cancer.
CareDx said its HistoMap gene expression profiling test will run on the Veracyte system. HistoMap is being developed using the Human Organ Transplant (HOT) panel from the Banff Foundation for Allograft Pathology.
The intention is to use the combined expertise in functional genomics and digital therapeutics to develop a range of health apps with pain management and COVID-19 the initial foci.
The companies said that the combination of their information and technologies will provide healthcare providers, payors, and employers with a simple solution to enable pharmacogenomics as a benefit.
Genomic data will be paired with de-identified health records from CCPM to aid in genomic medicine, drug discovery, and personalized medicine approaches, which the partners foresee enabling precision medicine.
The kit, which provides results in roughly one hour, is the first FDA EUA for the use of CRISPR technology in a diagnostic.
The technique could help study how genetic variants in different people affect which genes are expressed during infection or response to drugs ,and could also increase efficiency of single-cell experiments, assisting research into transplants, personalized medicine, and malaria.